Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | CCR4 | P51679 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23694374 | 0.81 | KDM4E (0.34) | KDM4EALDH1A1NOTUMCCR4 | |
| SCHEMBL2110629 | 0.73 | KDM4E (0.42) | KDM4EALDH1A1CCR4 | |
| SCHEMBL7235694 | 0.73 | KDM4E (0.42) | KDM4EALDH1A1 | |
| SCHEMBL31080718 | 0.73 | ALDH1A1 (0.37) | KDM4EALDH1A1 | |
| SCHEMBL14734330 | 0.70 | HTT (0.36) | KDM4EALDH1A1 | |
| SCHEMBL10032805 | 0.70 | KDM4E (0.35) | KDM4EALDH1A1 | |
| SCHEMBL22444361 | 0.69 | KDM4E (0.38) | KDM4EALDH1A1 | |
| SCHEMBL2684164 | 0.69 | KDM4E (0.39) | KDM4EALDH1A1 | |
| SCHEMBL29792794 | 0.69 | KDM4E (0.39) | KDM4EALDH1A1 | |
| SCHEMBL29870786 | 0.69 | KDM4E (0.39) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11466016-B2 | Pharmaceutical compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2022-10-11 | — | — | US | disclosed |
| CN-114206885-A | Pyrazolo [3,4-B ] pyrazine SHP2 phosphatase inhibitors | 大冢制药株式会社 | 2022-03-18 | — | — | CN | disclosed |
| US-20210107908-A1 | PHARMACEUTICAL COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-04-15 | — | — | US | disclosed |
| US-20210107908-A1 | PHARMACEUTICAL COMPOUNDS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-04-15 | — | — | US | disclosed |
| EP-3759111-A1 | PHARMACEUTICAL COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2021-01-06 | — | — | EP | disclosed |
| CN-111902415-A | Pharmaceutical compounds | 大冢制药株式会社 | 2020-11-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210107908-A1 | PHARMACEUTICAL COMPOUNDS | MAPT, CYP3A5, SLC5A1 | KDM4E 2767/4885ALDH1A1 703/4885NOTUM 1617/4885 |
| US-11466016-B2 | Pharmaceutical compounds | MAPT, CYP3A5, SLC5A1 | KDM4E 2767/4885ALDH1A1 703/4885NOTUM 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.